Emerging Trends in Head and Neck Cancer Treatment: Advanced Imaging Modalities and Personalized Therapy
Christina Henson, MD, discusses unmet needs among patients with head and neck cancer.
Christina Henson, MD, radiation oncologist at The University of Oklahoma, discusses unmet needs among patients with head and neck cancer. Here, she discusses studies investigating how to best customize treatment for these patients, especially regarding deescalating treatment to avoid unnecessary toxicities.
Transcription:
0:05 | So far, we haven't found the kind of magic solution or the best way to deescalate on a large scale, but there have been a lot of really promising smaller studies selecting more niche groups of patients either with advanced imaging modalities that aren't necessarily available everywhere but that are able to kind of measure the tumor biology during the course of treatment and use that to determine who's having a good response and who's not having a good response and have the option to stop treatment earlier at lower doses for patients who are responding well.
0:45 | So everyone's hopeful that some time in the near future one of or more than one of is these studies will pan out in a widely applicable way that will be very beneficial for our patients.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
